Krystal Biotech (KRYS) IPO Opens Modestly Higher

Go back to Krystal Biotech (KRYS) IPO Opens Modestly Higher

Krystal Biotech Announces Pricing of Upsized Initial Public Offering

September 19, 2017 4:46 PM UTC

PITTSBURGH, Pa., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Krystal), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced the pricing of its initial public offering. The offering was upsized to 3,960,000 shares of common stock at a price to the public of $10.00 per share for aggregate gross proceeds of $39,600,000, before underwriting discounts, commissions and expenses.  In addition, Krystal has granted the underwriters a 30-day option to purchase up to an additional 594,000 shares of common stock to cover over-allotments, if any. The Companys stock is expected to begin... More